Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00LSW
|
|||
| Former ID |
DIB013915
|
|||
| Drug Name |
VA-111913
|
|||
| Synonyms |
VA-111913 TS; VA-913; VT-913; V1a antagonists (dysmenorrhea), Vantia; Vasopressin 1a antagonists (dysmenorrhea), Vantia/Ferring
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Dysmenorrhea [ICD-11: GA34.3; ICD-9: 625.3] | Phase 2 | [1] | |
| Company |
Ferring Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H21ClFN5O2
|
|||
| Canonical SMILES |
CN1C2=C(CN(C3=C(N2)C=C(C=C3)Cl)C(=O)C4=CC(=C(C=C4)CNC(=O)C5CC5)F)C=N1
|
|||
| InChI |
1S/C23H21ClFN5O2/c1-29-21-16(11-27-29)12-30(20-7-6-17(24)9-19(20)28-21)23(32)14-4-5-15(18(25)8-14)10-26-22(31)13-2-3-13/h4-9,11,13,28H,2-3,10,12H2,1H3,(H,26,31)
|
|||
| InChIKey |
VOEZSPDOPDPGSY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 877856-17-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin V1a receptor (V1AR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Reactome | Vasopressin-like receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00963053) VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Avarx. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.